High-throughput DNA sequencing of human gliomas identified mutually exclusive somatic mutations in either IDH1 or IDH2 in approximately 70% of secondary glioblastomas and grade II–III gliomas [4]. This evidence concerns the gene IDH1 and central nervous system cancer.